西托溴铵 | 51598-60-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 中文名称: 西托溴铵
• 中文别名: 溴化N-(环丙基甲基)东莨菪碱
• 英文名称: Cimetropium bromide
• CAS: 51598-60-8
• 化学式: Br*C₂₁H₂₈NO₄
• 分子量: 438.362
• InChiKey: WDURTRGFUGAJHA-GSWUYBTGSA-M

物化性质

• 熔点：
  174°
• 比旋光度：
  D20 -18.3° (c = 3)
• 溶解度：
  DMSO（少许）、甲醇（少许）、水（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.15
• 重原子数：
  27.0
• 可旋转键数：
  6.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  59.06
• 氢给体数：
  1.0
• 氢受体数：
  4.0

制备方法与用途

生物活性

Cimetropium Bromide (DA-3177) 是一种毒蕈碱受体拮抗剂，用于长期研究肠易激综合征。

靶点

mAChR

体外研究

Cimetropium Bromide 在孤立的来自不同物种的大鼠和豚鼠结肠准备中作为毒蕈碱介导收缩的竞争性拮抗剂表现出行为。其亲和力值（pA2）范围在7.41到7.82之间。这种药物在抑制纵行肌肉制备中的收缩方面具有强烈的抗毒蕈碱效果。在预先加载标记胆碱的制备物中进行灌注实验时，在毒蕈碱自身抑制被阻断的情况下，Cimetropium 减少了由电场刺激诱导的标记乙酰胆碱（ACh）释放。

体内研究

当通过静脉注射给药给具有结肠Thiry瘘管的清醒狗时，Cimetropium Bromide 是一种强效的大肠运动抑制剂，对内源性和外源性刺激引发的均表现出强大的抑制作用。在10-100 μg/kg 的剂量范围内，该药物能够拮抗新斯的明引起的结肠动力反应，其半数有效浓度（ID50）为27.9 μg/kg；无论是静息状态还是节律性收缩响应都受到影响。在类似剂量范围（3-100 μg/kg），Cimetropium Bromide 还抑制了由管腔膨胀引发的运动活性。

化学性质

从乙腈中结晶，熔点为174℃。[α]D20 - 18.3°(C=3)。

用途

Cimetropium Bromide 能阻断内脏平滑肌上的毒蕈碱型受体，具有抗毒蕈碱作用，并能缓解平滑肌痉挛。适用于胆石绞痛、肾绞痛、胃肠道痉挛疼痛、胆道和尿路痉挛疼痛、痛经及分娩疼痛等。

生产方法

由化合物（Ⅰ）和环丙基溴甲烷在乙腈中回流15～99小时，得到西托溴铵。

文献信息

• PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1447401A1

  公开（公告）日：2004-08-18

  A piperidin-2-one derivative compound represented by formula (I): wherein all symbols are described in the specification, or a non-toxic salt thereof. The compound represented by formula (I) inhibits activation of p38MAP kinase, and is useful for prevention and/or treatment of various inflammatory diseases, rheumatoid arthritis, osteoarthritis, arthritis, osteoporosis, autoimmune diseases, infectious diseases, sepsis, cachexia, cerebral infarction, Alzheimer's disease, asthma, chronic pulmonary inflammatory diseases, reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft versus host rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, tumor growth and metastasis, multiple myeloma, plasma cell leukemia, Castleman's disease, atrial myxoma, psoriasis, dermatitis, gout, adult respiratory distress syndrome (ARDS), arteriosclerosis, post-percutaneous transluminal coronary angioplasty (PTCA) restenosis or pancreatitis.

  一个由公式(I)表示的哌啶-2-酮衍生物化合物： 其中所有符号都在说明书中描述，或其无毒盐。 由公式(I)表示的化合物能抑制p38MAP激酶的激活，并且可用于预防或治疗各种炎症性疾病、类风湿性关节炎、骨关节炎、关节炎、骨质疏松症、自身免疫病、感染性疾病、败血症、恶病质、脑梗塞、阿尔茨海默病、哮喘、慢性肺泡炎、再灌注损伤、血栓形成、肾小球肾炎、糖尿病、移植物抗宿主病、炎症性肠病、克罗恩病、溃疡性结肠炎、多发性硬化症、肿瘤生长和转移、多发性骨髓瘤、浆细胞白血病、卡斯尔曼病、心房粘液瘤、银屑病、皮炎、痛风、成人呼吸窘迫综合征（ARDS）、动脉硬化、经皮腔内冠状动脉成形术（PTCA）后再狭窄或胰腺炎。
• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient
  申请人：Ohhata Akira

  公开号：US20050222138A1

  公开（公告）日：2005-10-06

  A nitrogen-containing bicyclic compound of formula (I) or a pharmaceutically acceptable salt thereof (wherein the symbols have the same meanings as described in the specification). The compound of formula (I) has an inhibitory activity against PDE7 and it is useful for the prevention and/or treatment of various diseases, i.e. autoimmune diseases (ulcerative colitis, Crohn's disease, rheumatism, psoriasis, multiple sclerosis, collagenosis, etc.), inflammatory diseases (obstructive pulmonary disease, sepsis, pancreatitis, sarcoidosis, nephritis, hepatitis, enteritis, etc.), allergic diseases (asthma, allergic rhinitis, allergic conjunctivitis, seasonal conjunctivitis, atopic dermatitis, etc.), rejection of organ transplants, serious graft versus host disease (GVHD), diabetic disease, osteoporosis, bone fracture, restenosis, atherosclerosis, obesity, ischemic reperfusion injury, depression, Parkinson's disease, dementia, leukemia, etc.

  化学式（I）的含氮双环化合物或其药用盐（其中符号的含义与说明书中描述的相同）。 化合物的化学式（I）具有对PDE7的抑制活性，对于预防和/或治疗各种疾病非常有用，即自身免疫性疾病（溃疡性结肠炎、克罗恩病、风湿病、牛皮癣、多发性硬化症、结缔组织病等）、炎症性疾病（慢性阻塞性肺病、败血症、胰腺炎、结节病、肾炎、肝炎、肠炎等）、过敏性疾病（哮喘、过敏性鼻炎、过敏性结膜炎、季节性结膜炎、特应性皮炎等）、器官移植排斥、严重移植物抗宿主病（GVHD）、糖尿病、骨质疏松症、骨折、再狭窄、动脉粥样硬化、肥胖症、缺血再灌注损伤、抑郁症、帕金森病、痴呆症、白血病等。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• [EN] TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS<br/>[FR] TRIAZOLOBENZAZÉPINES UTILISÉES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE LA VASOPRESSINE V1A
  申请人：RICHTER GEDEON NYRT

  公开号：WO2019116324A1

  公开（公告）日：2019-06-20

  The present invention relates to 5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepine derivatives of general formula (I) and/or salts thereof and/or geometric isomers thereof and/or stereoisomers thereof and/or enantiomers thereof and/or racemates thereof and/or diastereomers thereof and/or biologically active metabolites thereof and/or prodrugs thereof and/or solvates thereof and/or hydrates thereof and/or polymorphs thereof which are centrally and/or peripherally acting V1a receptor modulators, particularly V1a receptor antagonists. Additional subject of the present invention is the process for the preparation of the compounds and the intermediates of the preparation process as well. The invention also relates to the pharmaceutical compositions containing the compounds or together with one or more other active substances, as well as to the use in the treatment and/or prophylaxis of a disease or condition associated with V1a receptor function.

  本发明涉及一般式(I)的5,6-二氢-4H-[1,2,4]三唑并[4,3-a][1]苯并蒽啉衍生物和/或其盐和/或其几何异构体和/或其立体异构体和/或其对映异构体和/或其消旋体和/或其非对映异构体和/或其生物活性代谢物和/或其前药和/或其溶剂化合物和/或其水合物和/或其多晶形式，这些化合物是中枢和/或外周作用的V1a受体调节剂，特别是V1a受体拮抗剂。本发明的另一个主题是制备这些化合物的过程以及制备过程的中间体。该发明还涉及含有这些化合物或与一个或多个其他活性物质一起的药物组合物，以及在治疗和/或预防与V1a受体功能相关的疾病或症状中的用途。